ENDRA Life Sciences (NDRA) Liabilities and Shareholders Equity (2016 - 2026)

ENDRA Life Sciences has disclosed Liabilities and Shareholders Equity across 11 years of filings, most recently posting $3.4 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 8.44% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $12.1 million (down 54.38% YoY), while the FY2025 annual figure was $3.9 million, down 13.44% from the prior year.
• Liabilities and Shareholders Equity declined to $3.4 million in Q1 2026, from $3.9 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for NDRA reached as high as $15.3 million in Q2 2022 and fell as low as $2.0 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $6.8 million (2023), against an average of $7.2 million.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity climbed 12.96% — and 2025, when it plunged 76.56%.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $9.3 million in 2022, then decreased by 27.17% to $6.8 million in 2023, then sank by 34.08% to $4.5 million in 2024, then declined by 13.44% to $3.9 million in 2025, then dropped by 10.78% to $3.4 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $3.4 million, $3.9 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.